# TABLE OF CONTENTS

INTRODUCTION ................................................................................................................... 1  
   Purpose, Scope, and Application .................................................................................... 1  
DEFINITIONS ......................................................................................................................... 2  
POLICY .................................................................................................................................. 4  
   Disclosure of Financial Interests ...................................................................................... 4  
   Review of Disclosures, Management Plans, and Monitoring ........................................ 4  
   Training and Education Regarding Conflicts to Investigators ...................................... 5  
   Sub-Recipients, Subcontractors and/or Consortium Members ...................................... 6  
   Reporting ......................................................................................................................... 6  
   Retrospective Review and Mitigation Reports ................................................................. 7  
   Records ............................................................................................................................ 8  
   Public Access to Information ......................................................................................... 8  
REFERENCES ....................................................................................................................... 9  
RELATED FORMS ................................................................................................................ 9  
RELATED PRACTICE DOCUMENTS .................................................................................. 9  
DOCUMENT HISTORY ........................................................................................................ 9
INTRODUCTION

Purpose, Scope, and Application

The federal Department of Health and Human Services (HHS) has determined, pursuant to 42 C.F.R. Part 50, Subpart F and 45 C.F.R. Part 94, as revised on August 25, 2011, that effective no later than August 24, 2012, Public Health Service (PHS) - sponsored Investigators shall be subject to specific requirements regarding the disclosure and management of conflicts of interest with regard to research in order to provide a reasonable expectation that PHS- sponsored research will be conducted free of bias resulting from Investigator financial conflicts of interest.

This policy for disclosure and management of conflicts of interest applies to all grants and cooperative agreements (other than Phase I SBIR and STTR applications) with an issue date of the Notice of Award on or after August 24, 2012 (including non-competing continuations) and to solicitations issued and contracts awarded after August 24, 2012 that are submitted to PHS (NIH, CDC, FDA, etc.) and other non-federal sponsors that adopt the PHS policy for research.

Ellison Institute is obligated to establish this policy consistent with these regulations to require disclosure, and identification and management of financial conflicts of interest for all Investigators supported by PHS (NIH, CDC, FDA, etc.) research awards and other non- federal sponsors that adopt the PHS policy, (for example, American Heart Association and the American Cancer Society).

Consistent with PHS regulations, this policy will be made available via a publicly accessible website. All Ellison Institute Investigators (that is, individuals who, regardless of position or title, are responsible for the design, conduct or reporting of PHS supported research, and Investigators seeking PHS research support) shall be informed where this policy and relevant reporting requirements may be accessed via the web.
DEFINITIONS

- **Designed Institutional Official**: The individual(s) at Ellison Institute responsible for implementing this Policy will be a team consisting of any two or more of the following: Supervisor, Human Resources partner, Chief Legal Officer; and CEO or President. The responsibility includes: ensuring completion of all disclosure of significant financial interests per the outlined policy below, reviewing all disclosures of Significant Financial Interests, Conflicts of Interest and Conflicts of Commitment, and requiring any and all actions necessary to ensure that any Conflict of Interest or Commitment found will be managed, reduced or eliminated in accordance with this Policy.

- **Financial Conflict of Interest**: Significant Financial Interest that is related to the PHS-funded research activity in which the Investigator is engaged and that could directly and significantly affect the design, conduct and/or reporting of PHS-funded research activity.

- **Independent Review Committee (IRC)**: A committee which may be appointed by the RIO to review Investigator’s significant financial interests related to PHS funded research, and to serve as regulatory body who determines whether any of the significant financial interest constitutes a financial conflict of interest. At the RIO’s discretion, this review may be conducted by the RIO or the IRC.

- **Key Personnel**: A PHS research Project Director, Principal Investigator and any other personnel considered essential to work performance and identified as Key Personnel in the contract proposal, grant, or contract.

- **Principal Investigator**: An Investigator who has primary responsibility for the scientific and technical conduct, reporting, fiscal and programmatic administration of a sponsored project.

- **Research**: As used in this Policy, any activity for which research funding is available from a PHS awarding agency, including but not limited to research grants, cooperative agreements, career development awards, center grants, individual fellowship awards, infrastructure awards, Institutional training grants, program projects or research resources awards, conference grants, and Phase II Small Business Innovative Research (SBIR) and Phase II Small Business Technology Transfer Research (STTR) awards. Excluded from this Policy, consistent with the underlying federal regulations, are Phase I Small Business Innovative Research (SBIR) and Phase I Small Business Technology Transfer Research (STTR) awards.

- **Research Integrity Officer (RIO)**: The RIO is the primary designated institutional official responsible for implementing this Policy. This will be the Chief Legal Officer; and CEO or President.
• **Significant Financial Interest (SFI):** Consistent with federal regulations (42 CFR Part 50.603 and 45 CFR Part 94.3), Significant Financial Interest means a financial interest consisting of one or more of the following interests of the Investigator or the Investigator’s spouse or registered domestic partner or dependent children for the following categories, except in the case of travel:

- With regard to any publicly traded entity, a Significant Financial Interest exists if the value of any remuneration (other than remuneration described in Paragraph II.H.5, below) received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds $5,000. Included are salary (other than salary described in Paragraph II.H.5, below), consulting fees, honoraria, and the equity interest value at the date of disclosure as determined by public prices or other reasonable measure of fair market value.

- With regard to any non-publicly traded entity, a Significant Financial Interest exists if the value of any remuneration (other than remuneration described in Paragraph II.H.5, below) received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (or the Investigator’s spouse, registered domestic partner, or dependent children) holds any equity interest.

- Intellectual property rights and interests, upon receipt of income, exceeding $5,000 during the twelve months preceding disclosure from such rights and interests.

- In the case of travel, sponsored travel or reimbursements made to or on behalf of, the Investigator, regardless of amount, by a for-profit or non-profit entity related to the Investigator’s Institutional Responsibilities. However, Significant Financial Interests do not include travel reimbursed or paid by federal, state, or local government agency, a U.S. institution of higher education, or a research institute, academic medical center or hospital affiliated with an institution of higher education.

- Ellison Institute Grants Administrator (EIGA): The office that is responsible for training and education on this policy, adherence to federal regulations governing human subjects’ research, and disclosure of significant financial interests to any Institutional Review Board overseeing Ellison Institute Research.
POLICY

Disclosure of Financial Interests

• All principal investigators and key personnel must disclose all potential conflicts of interest of themselves or their spouses/domestic partners and dependent children on the appropriate FCOI disclosure form(s):
  • At the time of application for PHS funding
  • Annually during IRB renewal
  • Within 30 days of discovering or acquiring (e.g., through purchase, marriage, or inheritance) a new Significant Financial Interest. Except for travel described below.)
  • Before joining an ongoing PHS-funded research project new Investigators

• Principal Investigators must identify all Investigators on the award who (that is, all individuals who will have responsibility for designing, conducting, or reporting the research to be funded by PHS) are required to disclose Significant Financial Interests.

• Sponsored or reimbursed travel may be disclosed:
  • Prospectively listing all anticipated travel (including information about the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration of the trip, as well as any other information that may be required by the sponsor/organizer) for the 12-month period following the filing of the Investigator’s annual disclosure form.
  • Within 30 days of the occurrence of travel that either was not listed on the prospective annual travel report pursuant to paragraph III.A.6.i. or that significantly varied in the threshold reporting details from what was listed in the prospective report.

Review of Disclosures, Management Plans, and Monitoring

• With each PHS proposal, progress report, incremental funding or extension, Investigators’ Significant Financial Interests disclosures will be reviewed by the RIO to determine whether there are any Significant Financial Interests that reasonably appear to be related to the PHS-funded research activity in which the Investigator is engaged.
• Investigators shall have an opportunity to indicate whether they believe the Significant Financial Interest(s) they reported are related to their PHS-funded research activities.

• In the event that the RIO concludes that an Investigator’s Significant Financial Interest reasonably appears to directly and significantly affect the design, conduct or reporting of the PHS-funded research; or is in an entity whose financial interest could be affected by the research, the Disclosure and appropriate documentation shall be forwarded to the IRC for consideration. When it is determined that there is a financial conflict of interest, the IRC shall make a final recommendation to the RIO about whether any conditions or restrictions should be placed on the project to eliminate or manage the Financial Conflict of Interest before the support can be accepted.

• The management plan is to be implemented prior to Ellison Institute’s expenditure of PHS funds awarded for the research project, and shall specify the actions that are required to manage the Financial Conflict of Interest, and shall include:
  • The role and principal duties of the conflicted Investigator
  • Conditions of the management plan
  • How the plan will safeguard objectivity in the research activity
  • Confirmation of the investigator’s agreement to the plan
  • How the plan will be monitored
  • The same review process takes place when an Investigator reports a new Significant Financial Interest.

• The management plan put in place by the RIO or IRC shall specify the way in which the Investigator’s compliance with the management will be monitored on an ongoing basis until completion of the PHS-funded research project.

Training and Education Regarding Conflicts to Investigators

EIGA shall make all Ellison Institute investigators aware of this policy, the disclosure requirement outlined below, provides links to federal regulations, and provides resources for them to complete an NIH-compliant training about the PHS financial conflicts of interest:
  • prior to engaging in research related to any PHS-funded project,
  • at least every 4-years thereafter,
• Immediately upon changes to Ellison Institute policy revisions, required in accordance with DHHS regulations.

• Immediately for PHS-funded Investigators who are new to Ellison Institute or who are joining from an ongoing PHS Research activity,

• Immediately when an Investigator is not in compliance with policy or management plan.

Sub-Recipients, Subcontractors and/or Consortium Members

For Public Health Services (PHS)-funded research where Ellison Institute is the awardee Institution, Ellison Institute will require the subrecipient institution to certify that its policy is in compliance with DHHS conflict of interest regulations, and unless the subrecipient does not have a DHHS-compliant policy, will indicate that the recipient organization is responsible for reviewing the disclosures submitted by its Investigators and, if a Financial Conflict of Interest is identified, for sending Ellison Institute notification of the conflict and of the subrecipient institution’s plan to manage, reduce or eliminate the identified conflicts, in accordance with PHS reporting requirements. For collaborators from other institutions who share responsibility for design, conduct or reporting research results, and who will be conducting research under a contracts from Ellison Institute are expected to comply with the policies and procedures for disclosure and review of a Significant Financial Interests at the institution at which they are employed or, if their institution does not have a conflict of interest policy that complies with the DHHS regulations, they must comply with Ellison Institute policies and procedures for disclosure and review of a Significant Financial Interests related to PHS sponsored awards.

Reporting

Prior to Ellison Institute’s expenditure of any funds provided under a PHS award, the RIO must provide to the PHS funding agency an initial report regarding Investigator Financial Conflict of Interest. If Financial Conflicts of Interest are eliminated before research funds are expended, Ellison Institute is not required to submit a report to the PHS funding agency.

During the period of the award, Ellison Institute shall, within 60 days of receipt of disclosure of a new or newly-discovered Significant Financial Interest, review the disclosure, determine whether it is related to PHS-funded research, determine whether it constitutes a Financial Conflict of Interest, and if so, implement a management plan and report the Financial Conflict of Interest to the PHS funding agency.
For any Financial Conflict of Interest that the Ellison Institute reports to a PHS awarding agency, Ellison Institute shall provide to the PHS awarding agency an annual Financial Conflict of Interest report that addresses the status of the conflict and any changes to the management plan, for the duration of the project. The annual report shall specify whether the financial conflict is still being managed or explain why it no longer exists.

Ellison Institute must provide annual reports to the PHS awarding agency for the duration of the project period (including extensions with or without funds).

Within 60 days of determining that a Financial Conflict of Interest exists for a new Investigator who joins an ongoing PHS-funded research activity, Ellison Institute must implement a management plan and submit a report to the PHS Funding agency.

In any case in which the Department of Health and Human Services (DHHS) determines that a PHS-sponsored project of clinical research whose purpose is to evaluate the safety or effectiveness of a drug, medical device or treatment has been designed, conducted, or reported by an Investigator with a Financial Conflict of Interest that was not managed or reported by Ellison Institute as required by this policy and Federal regulation, Ellison Institute shall require the Investigator to disclose the Financial Conflict of Interest in each public presentation of the results of the research and to request an addendum to previously published presentations.

**Retrospective Review and Mitigation Reports**

When during the course on ongoing PHS-funded research project, Ellison Institute identifies a Significant Financial Interest that was not disclosed in a timely manner by an Investigator or which was not previously reviewed, the RIO will, within 60 days, review the Significant Financial Interest to determine whether it is related to PHS funded research activity, determine whether a Financial Conflict of Interest exists, and if so, implement a management plan on at least an interim basis.

In addition, whenever a Financial Conflict of Interest is not identified or managed in a timely manner, regardless of whether the Investigator did not disclose an SFI that was later determined to be a Financial Conflict of Interest, or Ellison Institute did not review or manage the Financial Conflict of Interest, or the Investigator failed to comply with a previously implemented management plan, Ellison Institute must within 120 days of the determination of non-compliance, complete a retrospective review of the Investigator’s activities and the PHS-funded research. The purpose of this retrospective review is to determine if the ongoing PHS-funded research was biased in its design, conduct or reporting.

The Ellison Institute will document the retrospective review; such documentation will include the project number; project title; name of Investigator with the Financial Conflict
of Interest; name of the entity with which the Investigator has a Financial Conflict of Interest; the reasons for the retrospective review; detailed methodology used for the retrospective review; findings; and conclusions.

Based on the results of the retrospective review, if appropriate, the previously submitted Financial Conflict of Interest report should be updated to specify the actions that Ellison Institute will take to manage the identified Financial Conflict of Interest going forward.

If bias was found during the retrospective review, Ellison Institute will promptly notify the PHS funding agency and will draft a mitigation report that at a minimum document the key elements of the retrospective review, describes the impact of the bias on the research, and outlines Ellison Institute’s plans to eliminate or mitigate the effect of the bias.

**Records**

Official records regarding individual conflicts of interest disclosures shall be maintained by Human Resources and retained for three years after submission of the final expenditures report or, for awards that are renewed quarterly or annually, from the date of submission of the quarterly or financial report, or from other dates specified in 45 CFR 75.361 where applicable.

**Public Access to Information**

The RIO shall identify one e-mail address and one office address as the recipient addresses for public requests for information under the PHS regulations and this policy shall act necessary to provide reasonable notice of those addresses to the public, including prominently posting this information on the campus web site.

The contact must respond within 5 business days to any request for information about Significant Financial Interests held by Key Personnel when Ellison Institute has determined that the disclosed Significant Financial Interests are related to the PHS funded research and constitute Financial Conflicts of Interest. The 5-day response time shall be measured from the date that the request for information is received at the campus-designated address until the date a response is sent to the requestor.

Disclosure forms, Disclosure Update forms, and Management Plans including determinations of Financial Conflicts of Interest under this policy are public records open to public inspection, under federal and state law.
REFERENCES
21 C.F.R. Part 54
42 C.F.R. Part 50
45 C.F.R. Part 94

RELATED FORMS
Research Conflict of Interest Disclosure Form, see attached “Appendix A.”

RELATED PRACTICE DOCUMENTS
Employees at Ellison Institute are expected to always conduct themselves in a professional manner. Ellison’s Team Handbook policy states that when acting on behalf of the Institute, you are expected to act in accordance with all applicable laws, rules and regulations and refrain from illegal activities. Any types of misconduct will not be tolerated including but not limited to, conduct that threatens the security, personal safety or welfare of employees or the Institute’s operations, or that is harmful or potentially harmful to the conduct of research will be prohibited and determination will be made by the Chief Legal Officer and President or CEO.

DOCUMENT HISTORY
Investigator Name: ____________________________

Project Title: ________________________________

Proposed Sponsor: ____________________________

PLEASE CHECK ONE OF THE FOLLOWING:

I have NO significant financial interests to disclose which relate to my institutional responsibilities. (If NO significant financial interests, please read the Certifications below and sign as “Investigator.”)

OR

I am disclosing significant financial interests (and those of my spouse and dependent children) which relate to my institutional responsibilities. (Please provide the following details regarding the entity, your financial interest, income and travel, then read the Certifications and sign below as “Investigator.”)

Name of Entity (corporation, partnership, private practice, non-publicly traded entities, etc.):

Address of Entity: ________________________________

Principal Type of Business: ________________________________

How does the financial interest relate to PHS-funded research?

Did remuneration received from the entity in the twelve months preceding the disclosure* (see exclusions below*) AND the value of any equity interest in the entity as of the date of disclosure, when aggregated, exceed $5,000?

Yes___ No___

*Exclusions -- excluded from income disclosure: NOT required to disclose income from seminars, lectures, or teaching engagements sponsored by and service on advisory or review panels for a federal, state or local government agency, an Institution of higher education as defined at 20 USC 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education. NOT required to disclose income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles.

Do you have income from an interest in any intellectual property rights impacted by the project?  Yes___No___
In the last 12 months, did you receive reimbursed or sponsored travel from the entity? **Yes** **No**

If “Yes,” please provide the following trip details:

1. Purpose of trip: __________________________________________
2. Sponsor/Organizer: _______________________________________
3. Destination: ___________________________________________
4. Duration: ______________________________________________

**Exclusions — excluded from travel disclosure:** NOT required to disclose travel that is reimbursed or sponsored by a federal, state, or local government agency, an Institution of higher education as defined at 20 USC 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education. The Institution will determine if any travel requires further investigation, including determination or disclosure of the monetary value.

### Investigator Certification:

- I agree to complete FCOI training prior to engaging in research related to any PHS/NIH-funded grant or contract and at least every four years thereafter; and, immediately upon other events, as defined per campus policy. Upon completion of each training session, I will send an email confirming completion to: **ADD IN EMAIL ADDRESS**
- If the proposed project is funded by PHS/NIH, I agree, for the duration of the project, to update this disclosure either on an annual basis, or within 30 days if new reportable significant financial interests are obtained (such as through purchase, marriage or inheritance, for example).
- I agree to provide additional details needed to meet NIH’s institutional filing, annual reporting and other requirements, and to cooperate in the development of a Resolution Plan to address any actual or potential conflict of interest identified via this Disclosure.
- If I participate in a project involving subrecipient organizations, I agree to assist Ellison Institute in obtaining required disclosures in a timely manner from all subrecipient Investigators, and to assist Ellison Institute, if requested, to manage any FCOIs of a subrecipient Investigator to assure compliance with these regulations.
- I agree to comply with any retrospective reviews, conditions or restrictions imposed by Ellison Institute to manage, reduce, or eliminate actual or potential conflicts of interest or forfeit the award.

Signed: _______________________________ Date: __________

Investigator

**To be Endorsed/Signed Only by Ellison Institute Official:**

I have reviewed the significant financial interest disclosure and believe that no significant financial interest exists or if one does exist that it is possible to develop and execute, prior to award, a Resolution Plan to manage, reduce or eliminate any actual or potential conflict of interest; and, therefore, I recommend that the proposal be submitted to the agency at this time.

Signed: _______________________________ Date: __________